Barry Investment Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.77M Sell
114,880
-5,522
-5% -$144K 0.58% 29
2026
Q1
$3.38M Sell
120,402
-1,488
-1% -$39.6K 0.75% 29
2025
Q4
$3.04M Sell
121,890
-15,029
-11% -$379K 0.68% 29
2025
Q3
$3.49M Sell
136,919
-18,173
-12% -$449K 0.8% 31
2025
Q2
$3.76M Buy
155,092
+221
+0.1% +$5.15K 0.94% 28
2025
Q1
$3.92M Sell
154,871
-19,916
-11% -$521K 1.04% 30
2024
Q4
$4.64M Sell
174,787
-23,362
-12% -$634K 1.49% 21
2024
Q3
$5.73M Buy
198,149
+314
+0.2% +$9.16K 1.75% 19
2024
Q2
$5.54M Buy
197,835
+5,262
+3% +$145K 1.86% 18
2024
Q1
$5.34M Buy
192,573
+2,123
+1% +$58.9K 1.78% 21
2023
Q4
$5.48M Sell
190,450
-643
-0.3% -$19.4K 1.85% 22
2023
Q3
$6.34M Buy
191,093
+458
+0.2% +$16.2K 2.28% 14
2023
Q2
$6.99M Sell
190,635
-2,826
-1% -$110K 2.36% 15
2023
Q1
$7.89M Buy
193,461
+2,283
+1% +$98.6K 2.59% 15
2022
Q4
$9.8M Sell
191,178
-1,986
-1% -$95.2K 3.09% 7
2022
Q3
$8.45M Sell
193,164
-5,868
-3% -$285K 2.9% 11
2022
Q2
$10.4M Sell
199,032
-12,821
-6% -$653K 3.13% 6
2022
Q1
$11M Sell
211,853
-8,494
-4% -$441K 2.91% 8
2021
Q4
$13M Sell
220,347
-2,779
-1% -$138K 3.43% 5
2021
Q3
$9.6M Sell
223,126
-1,972
-0.9% -$87.4K 2.66% 9
2021
Q2
$8.81M Sell
225,098
-4,410
-2% -$171K 2.36% 13
2021
Q1
$8.31M Buy
229,508
+7,598
+3% +$270K 2.29% 17
2020
Q4
$8.17M Sell
221,910
-10,673
-5% -$391K 2.41% 16
2020
Q3
$8.1M Buy
232,583
+2,018
+0.9% +$70.8K 2.78% 13
2020
Q2
$7.15M Buy
230,565
+3,957
+2% +$134K 2.53% 17
2020
Q1
$7.02M Buy
226,608
+2,661
+1% +$90.7K 3.48% 10
2019
Q4
$8.37M Buy
223,947
+3,387
+2% +$121K 2.94% 12
2019
Q3
$7.52M Sell
220,560
-2,145
-1% -$78K 2.72% 13
2019
Q2
$9.15M Sell
222,705
-2,709
-1% -$108K 3.14% 11
2019
Q1
$9.08M Sell
225,414
-6,220
-3% -$249K 2.84% 13
2018
Q4
$9.59M Buy
231,634
+1,149
+0.5% +$47.7K 3.59% 10
2018
Q3
$9.64M Sell
230,485
-73,723
-24% -$2.84M 3.24% 12
2018
Q2
$10.5M Sell
304,208
-1,097
-0.4% -$37.5K 4.01% 7
2018
Q1
$10.3M Sell
305,305
-8,462
-3% -$291K 3.9% 9
2017
Q4
$10.8M Sell
313,767
-2,088
-0.7% -$71.2K 4% 9
2017
Q3
$10.7M Buy
315,855
+51
+0% +$1.64K 3.95% 9
2017
Q2
$10.1M Sell
315,804
-2,532
-0.8% -$79.8K 3.8% 9
2017
Q1
$10.3M Sell
318,336
-5,808
-2% -$183K 3.83% 8
2016
Q4
$9.99M Sell
324,144
-5,647
-2% -$172K 3.5% 9
2016
Q3
$10.6M Sell
329,791
-486
-0.1% -$16.3K 3.65% 9
2016
Q2
$11M Sell
330,277
-5,789
-2% -$185K 4.29% 4
2016
Q1
$9.45M Sell
336,066
-2,439
-0.7% -$69.7K 3.01% 9
2015
Q4
$10.4M Sell
338,505
-11,902
-3% -$374K 3.37% 7
2015
Q3
$10.4M Sell
350,407
-1,450
-0.4% -$46.5K 3.35% 6
2015
Q2
$11.2M Sell
351,857
-2,305
-0.7% -$75.1K 11.26% 1
2015
Q1
$11.7M Sell
354,162
-8,475
-2% -$269K 3.57% 6
2014
Q4
$10.7M Buy
+362,637
New +$10.4M 3.48% 8

Other funds holding PFE

Barry Investment Advisors's PFE Position: Q2 2026 in Review

Barry Investment Advisors reduced its Pfizer (PFE) stake by 4.6% in Q2 2026, selling an estimated $144K and leaving 114,880 shares worth $2.77M. The position accounts for 0.58% of the portfolio, ranked #29.

Barry Investment Advisors first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $13M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Barry Investment Advisors held 114,880 shares of Pfizer worth $2.77M as of Q2 2026.
  • Barry Investment Advisors sold 5,522 Pfizer shares in Q2 2026, an estimated $144K.
  • Pfizer made up 0.58% of Barry Investment Advisors's portfolio in Q2 2026, its #29 holding.
  • Barry Investment Advisors first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
  • Barry Investment Advisors's Pfizer position peaked at $13M in Q4 2021.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Barry Investment Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.